VistaGen Therapeutics, Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (33)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou
Article By: ChinaBio® Today
Saturday, April 16, 2022 3:11 PM EDT
Deals, financings, trials and approvals in biotech in China this week.
In this article: BGNE, VTGN
Read
S VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Article By: Moon Kil Woong
Friday, January 8, 2021 11:59 AM EDT
VistaGen’s deal with Pherin Pharmaceuticals to develop PH-94B has positioned the Company to grab a healthy share of, social anxiety, and major depression markets.
In this article: JNJ, SAGE, CNSP, AXSM, RLMD, VTGN
Read
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
Article By: TalkMarkets Newswire
Thursday, July 23, 2020 9:00 AM EDT
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
In this article: VTGN Also: IMMP, ARTX, SAGE, RLMD, BHVN
Read
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Article By: ChinaBio® Today
Saturday, June 27, 2020 2:00 PM EDT
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
In this article: VTGN Also: AGEN, HCM, GTHX, SEQUX, GILD, MRK
Read
VistaGen Therapeutics And EverInsight Therapeutics Enter Strategic Collaboration To Develop And Commercialize PH94B For Anxiety Disorders In Greater China, South Korea And Southeast Asia
Article By: TalkMarkets Newswire
Thursday, June 25, 2020 8:03 AM EDT
The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.
In this article: VTGN Also: ARTX, SAGE, RLMD, BHVN
Read
All Posts

Latest Tweets for $VTGN

No tweets yet!

PARTNER HEADLINES

$VTGN

Comments Status Updates
Rotation Opportunity As Three Top Psychedelic Stocks Explode
Corey Gaber • 12/15/2020 3:37:26 AM

Great article @TalkMarkets $MMEDF has been a BANGER $VTGN

is Kim Jong gonna make everyone take PH10??!!!!

VistaGen Therapeutics: Interesting Prospects
Alexis Renault • 10/5/2017 7:43:59 PM

Thanks Terry! Will take a closer look at $VTGN.

VistaGen Therapeutics: Interesting Prospects
Derek Snyder • 10/4/2017 9:07:54 AM

Your argument for acquisition sounds convincing, but I wonder if there have been any such overtures. Know if that's the case? Which companies would be the most likely to target #Vistagen? $VTGN.

VistaGen Therapeutics: Interesting Prospects
David M. Green • 10/4/2017 2:43:18 AM

Looks promising. Sounds like $VTGN should be getting more love from investors.

VistaGen Therapeutics: Interesting Prospects
Bill Johnson • 10/3/2017 10:34:18 PM

Definitely sounds like some interesting prospects indeed! $VTGN

1 to 5 of 5 comments